SrasV1, PascalFrancis, Curation, bibRecord, 000374

Evaluation of a peptide-based enzyme immunoassay for anti-SARS coronavirus IgG antibody

Identifieur interne : 000374 ( PascalFrancis/Curation ); précédent : 000373; suivant : 000375

Evaluation of a peptide-based enzyme immunoassay for anti-SARS coronavirus IgG antibody

Auteurs : Paul K. S. Chan [Hong Kong] ; W. K. To [Hong Kong] ; Esther Y. M. Liu [Hong Kong] ; T. K. Ng [Hong Kong] ; John S. Tam [Hong Kong] ; Joseph J. Y. Sung [Hong Kong] ; Jean-Michel Lacroix [Canada] ; Michel Houde [Canada]

Source :

Journal of medical virology [ 0146-6615 ] ; 2004.

RBID : Pascal:05-0395225

Descripteurs français

Pascal (Inist)
- Virus syndrome respiratoire aigu sévère, Peptide, Méthode immunoenzymatique, IgG, Anticorps, Sérologie, Syndrome respiratoire aigu sévère.

English descriptors

KwdEn :
- Antibody, Enzyme immunoassay, IgG, Peptides, Serology, Severe acute respiratory syndrome, Severe acute respiratory syndrome virus.

Abstract

High throughput assays for anti-SARS-CoV IgG antibody detection are need for large-scale epidemiologic studies. The performance of a microplate enzyme immunoassay, DETECT-SARS, was evaluated for the detection of anti-SARS-CoV IgG antibody. This assay is based on synthetic peptides derived from the nucleocapsid and spike proteins. The results showed that the assay provided a high degree of sensitivity (95.9%) for convalescent serum samples. The level of specificity was close to 90%, and did not show significant variation among different control groups. The high degree of sensitivity together with the high-throughput nature makes it advantageous as a screening assay for studies where handling of a large number of specimens is required.

A01	`01`	`1`		`@0 0146-6615`
A02	`01`			`@0 JMVIDB`
A03		`1`		`@0 J. med. virol.`
A05				`@2 74`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 Evaluation of a peptide-based enzyme immunoassay for anti-SARS coronavirus IgG antibody`
A11	`01`	`1`		`@1 CHAN (Paul K. S.)`
A11	`02`	`1`		`@1 TO (W. K.)`
A11	`03`	`1`		`@1 LIU (Esther Y. M.)`
A11	`04`	`1`		`@1 NG (T. K.)`
A11	`05`	`1`		`@1 TAM (John S.)`
A11	`06`	`1`		`@1 SUNG (Joseph J. Y.)`
A11	`07`	`1`		`@1 LACROIX (Jean-Michel)`
A11	`08`	`1`		`@1 HOUDE (Michel)`
A14	`01`			`@1 Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Prince of Wales Hospital @2 Shatin, New Territories @3 HKG @Z 1 aut. @Z 5 aut. @Z 6 aut.`
A14	`02`			`@1 Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital @2 Shatin, New Territories @3 HKG @Z 1 aut. @Z 3 aut. @Z 5 aut.`
A14	`03`			`@1 Department of Pathology, Princess Margaret Hospital @2 Kowloon, Shatin, New Territories @3 HKG @Z 2 aut. @Z 4 aut.`
A14	`04`			`@1 Adaltis Development, Inc. @2 Montreal, Quebec @3 CAN @Z 7 aut. @Z 8 aut.`
A20				`@1 517-520`
A21				`@1 2004`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 17422 @5 354000122446470010`
A44				`@0 0000 @1 © 2005 INIST-CNRS. All rights reserved.`
A45				`@0 17 ref.`
A47	`01`	`1`		`@0 05-0395225`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of medical virology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 High throughput assays for anti-SARS-CoV IgG antibody detection are need for large-scale epidemiologic studies. The performance of a microplate enzyme immunoassay, DETECT-SARS, was evaluated for the detection of anti-SARS-CoV IgG antibody. This assay is based on synthetic peptides derived from the nucleocapsid and spike proteins. The results showed that the assay provided a high degree of sensitivity (95.9%) for convalescent serum samples. The level of specificity was close to 90%, and did not show significant variation among different control groups. The high degree of sensitivity together with the high-throughput nature makes it advantageous as a screening assay for studies where handling of a large number of specimens is required.
C02	`01`	`X`		`@0 002A05C10`
C02	`02`	`X`		`@0 002B05C02J`
C02	`03`	`X`		`@0 002A05C08`
C03	`01`	`X`	`FRE`	`@0 Virus syndrome respiratoire aigu sévère @2 NW @5 01`
C03	`01`	`X`	`ENG`	`@0 Severe acute respiratory syndrome virus @2 NW @5 01`
C03	`01`	`X`	`SPA`	`@0 Severe acute respiratory syndrome virus @2 NW @5 01`
C03	`02`	`X`	`FRE`	`@0 Peptide @5 05`
C03	`02`	`X`	`ENG`	`@0 Peptides @5 05`
C03	`02`	`X`	`SPA`	`@0 Péptido @5 05`
C03	`03`	`X`	`FRE`	`@0 Méthode immunoenzymatique @5 06`
C03	`03`	`X`	`ENG`	`@0 Enzyme immunoassay @5 06`
C03	`03`	`X`	`SPA`	`@0 Método inmunoenzimático @5 06`
C03	`04`	`X`	`FRE`	`@0 IgG @5 07`
C03	`04`	`X`	`ENG`	`@0 IgG @5 07`
C03	`04`	`X`	`SPA`	`@0 IgG @5 07`
C03	`05`	`X`	`FRE`	`@0 Anticorps @5 08`
C03	`05`	`X`	`ENG`	`@0 Antibody @5 08`
C03	`05`	`X`	`SPA`	`@0 Anticuerpo @5 08`
C03	`06`	`X`	`FRE`	`@0 Sérologie @5 09`
C03	`06`	`X`	`ENG`	`@0 Serology @5 09`
C03	`06`	`X`	`SPA`	`@0 Serología @5 09`
C03	`07`	`X`	`FRE`	`@0 Syndrome respiratoire aigu sévère @2 NM @5 14`
C03	`07`	`X`	`ENG`	`@0 Severe acute respiratory syndrome @2 NM @5 14`
C03	`07`	`X`	`SPA`	`@0 Síndrome respiratorio agudo severo @2 NM @5 14`
C07	`01`	`X`	`FRE`	`@0 Coronavirus @2 NW`
C07	`01`	`X`	`ENG`	`@0 Coronavirus @2 NW`
C07	`01`	`X`	`SPA`	`@0 Coronavirus @2 NW`
C07	`02`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`03`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`04`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`04`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`04`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`05`	`X`	`FRE`	`@0 Appareil respiratoire pathologie @5 13`
C07	`05`	`X`	`ENG`	`@0 Respiratory disease @5 13`
C07	`05`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 13`
C07	`06`	`X`	`FRE`	`@0 Virose`
C07	`06`	`X`	`ENG`	`@0 Viral disease`
C07	`06`	`X`	`SPA`	`@0 Virosis`
C07	`07`	`X`	`FRE`	`@0 Infection`
C07	`07`	`X`	`ENG`	`@0 Infection`
C07	`07`	`X`	`SPA`	`@0 Infección`
C07	`08`	`X`	`FRE`	`@0 Poumon pathologie @5 16`
C07	`08`	`X`	`ENG`	`@0 Lung disease @5 16`
C07	`08`	`X`	`SPA`	`@0 Pulmón patología @5 16`
N21				`@1 276`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000616

Links to Exploration step

Pascal:05-0395225

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Evaluation of a peptide-based enzyme immunoassay for anti-SARS coronavirus IgG antibody</title>
<author><name sortKey="Chan, Paul K S" sort="Chan, Paul K S" uniqKey="Chan P" first="Paul K. S." last="Chan">Paul K. S. Chan</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="To, W K" sort="To, W K" uniqKey="To W" first="W. K." last="To">W. K. To</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Pathology, Princess Margaret Hospital</s1>
<s2>Kowloon, Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Liu, Esther Y M" sort="Liu, Esther Y M" uniqKey="Liu E" first="Esther Y. M." last="Liu">Esther Y. M. Liu</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Ng, T K" sort="Ng, T K" uniqKey="Ng T" first="T. K." last="Ng">T. K. Ng</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Pathology, Princess Margaret Hospital</s1>
<s2>Kowloon, Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Tam, John S" sort="Tam, John S" uniqKey="Tam J" first="John S." last="Tam">John S. Tam</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Sung, Joseph J Y" sort="Sung, Joseph J Y" uniqKey="Sung J" first="Joseph J. Y." last="Sung">Joseph J. Y. Sung</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Lacroix, Jean Michel" sort="Lacroix, Jean Michel" uniqKey="Lacroix J" first="Jean-Michel" last="Lacroix">Jean-Michel Lacroix</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Adaltis Development, Inc.</s1>
<s2>Montreal, Quebec</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Houde, Michel" sort="Houde, Michel" uniqKey="Houde M" first="Michel" last="Houde">Michel Houde</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Adaltis Development, Inc.</s1>
<s2>Montreal, Quebec</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0395225</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 05-0395225 INIST</idno>
<idno type="RBID">Pascal:05-0395225</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000616</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000374</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Evaluation of a peptide-based enzyme immunoassay for anti-SARS coronavirus IgG antibody</title>
<author><name sortKey="Chan, Paul K S" sort="Chan, Paul K S" uniqKey="Chan P" first="Paul K. S." last="Chan">Paul K. S. Chan</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="To, W K" sort="To, W K" uniqKey="To W" first="W. K." last="To">W. K. To</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Pathology, Princess Margaret Hospital</s1>
<s2>Kowloon, Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Liu, Esther Y M" sort="Liu, Esther Y M" uniqKey="Liu E" first="Esther Y. M." last="Liu">Esther Y. M. Liu</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Ng, T K" sort="Ng, T K" uniqKey="Ng T" first="T. K." last="Ng">T. K. Ng</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Pathology, Princess Margaret Hospital</s1>
<s2>Kowloon, Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Tam, John S" sort="Tam, John S" uniqKey="Tam J" first="John S." last="Tam">John S. Tam</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Sung, Joseph J Y" sort="Sung, Joseph J Y" uniqKey="Sung J" first="Joseph J. Y." last="Sung">Joseph J. Y. Sung</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Lacroix, Jean Michel" sort="Lacroix, Jean Michel" uniqKey="Lacroix J" first="Jean-Michel" last="Lacroix">Jean-Michel Lacroix</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Adaltis Development, Inc.</s1>
<s2>Montreal, Quebec</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Houde, Michel" sort="Houde, Michel" uniqKey="Houde M" first="Michel" last="Houde">Michel Houde</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Adaltis Development, Inc.</s1>
<s2>Montreal, Quebec</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of medical virology</title>
<title level="j" type="abbreviated">J. med. virol.</title>
<idno type="ISSN">0146-6615</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of medical virology</title>
<title level="j" type="abbreviated">J. med. virol.</title>
<idno type="ISSN">0146-6615</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibody</term>
<term>Enzyme immunoassay</term>
<term>IgG</term>
<term>Peptides</term>
<term>Serology</term>
<term>Severe acute respiratory syndrome</term>
<term>Severe acute respiratory syndrome virus</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Virus syndrome respiratoire aigu sévère</term>
<term>Peptide</term>
<term>Méthode immunoenzymatique</term>
<term>IgG</term>
<term>Anticorps</term>
<term>Sérologie</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">High throughput assays for anti-SARS-CoV IgG antibody detection are need for large-scale epidemiologic studies. The performance of a microplate enzyme immunoassay, DETECT-SARS, was evaluated for the detection of anti-SARS-CoV IgG antibody. This assay is based on synthetic peptides derived from the nucleocapsid and spike proteins. The results showed that the assay provided a high degree of sensitivity (95.9%) for convalescent serum samples. The level of specificity was close to 90%, and did not show significant variation among different control groups. The high degree of sensitivity together with the high-throughput nature makes it advantageous as a screening assay for studies where handling of a large number of specimens is required.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0146-6615</s0>
</fA01>
<fA02 i1="01"><s0>JMVIDB</s0>
</fA02>
<fA03 i2="1"><s0>J. med. virol.</s0>
</fA03>
<fA05><s2>74</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Evaluation of a peptide-based enzyme immunoassay for anti-SARS coronavirus IgG antibody</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>CHAN (Paul K. S.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>TO (W. K.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>LIU (Esther Y. M.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>NG (T. K.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>TAM (John S.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>SUNG (Joseph J. Y.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>LACROIX (Jean-Michel)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>HOUDE (Michel)</s1>
</fA11>
<fA14 i1="01"><s1>Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital</s1>
<s2>Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Pathology, Princess Margaret Hospital</s1>
<s2>Kowloon, Shatin, New Territories</s2>
<s3>HKG</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Adaltis Development, Inc.</s1>
<s2>Montreal, Quebec</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA20><s1>517-520</s1>
</fA20>
<fA21><s1>2004</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>17422</s2>
<s5>354000122446470010</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>17 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>05-0395225</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of medical virology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>High throughput assays for anti-SARS-CoV IgG antibody detection are need for large-scale epidemiologic studies. The performance of a microplate enzyme immunoassay, DETECT-SARS, was evaluated for the detection of anti-SARS-CoV IgG antibody. This assay is based on synthetic peptides derived from the nucleocapsid and spike proteins. The results showed that the assay provided a high degree of sensitivity (95.9%) for convalescent serum samples. The level of specificity was close to 90%, and did not show significant variation among different control groups. The high degree of sensitivity together with the high-throughput nature makes it advantageous as a screening assay for studies where handling of a large number of specimens is required.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05C10</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05C02J</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002A05C08</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Virus syndrome respiratoire aigu sévère</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Peptide</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Peptides</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Péptido</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Méthode immunoenzymatique</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Enzyme immunoassay</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Método inmunoenzimático</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>IgG</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>IgG</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>IgG</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Anticorps</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Antibody</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Anticuerpo</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Sérologie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Serology</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Serología</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0>
<s5>13</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>13</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>13</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Poumon pathologie</s0>
<s5>16</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Lung disease</s0>
<s5>16</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Pulmón patología</s0>
<s5>16</s5>
</fC07>
<fN21><s1>276</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000374 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000374 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:05-0395225
   |texte=   Evaluation of a peptide-based enzyme immunoassay for anti-SARS coronavirus IgG antibody
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Evaluation of a peptide-based enzyme immunoassay for anti-SARS coronavirus IgG antibody

Evaluation of a peptide-based enzyme immunoassay for anti-SARS coronavirus IgG antibody

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri